CN118059213A - Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 - Google Patents
Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 Download PDFInfo
- Publication number
- CN118059213A CN118059213A CN202311855472.0A CN202311855472A CN118059213A CN 118059213 A CN118059213 A CN 118059213A CN 202311855472 A CN202311855472 A CN 202311855472A CN 118059213 A CN118059213 A CN 118059213A
- Authority
- CN
- China
- Prior art keywords
- ocular
- neovascularization
- choroidal neovascularization
- medicament
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 208000005590 Choroidal Neovascularization Diseases 0.000 title claims abstract description 9
- 206010060823 Choroidal neovascularisation Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 7
- 206010029113 Neovascularisation Diseases 0.000 claims abstract description 15
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 206010029240 Neuritis Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000004245 retinal neuroinflammation Effects 0.000 abstract description 3
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 abstract description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 abstract description 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract description 2
- 238000012014 optical coherence tomography Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010051288 Central nervous system inflammation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101150012417 IL1B gene Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100273740 Mus musculus Cd68 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- -1 ccl-2 Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了PD‑1在制备治疗眼部脉络膜新生血管药物中的应用，所述的应用为抑制眼部视网膜神经炎症，抑制眼内新生血管的渗漏，可辅助治疗新生血管性年龄相关性黄斑变性。
Description
技术领域
本发明具体涉及PD-1新用途技术领域，具体涉及PD-1相关制剂在制备治疗眼部新生血管药物中的应用。
背景技术
新生血管性年龄相关性黄斑变性是引起老年人口不可逆视力丧失的主要原因。其病变特征为眼部病理性新生血管，会引起严重的视力丧失甚至失明。
目前主要的治疗方法为抗VEGF药物，虽然有较好的疗效，但是仍有部分患者对治疗不敏感。而且抗VEGF需要反复多次注射，可能会引起白内障，青光眼，眼内炎等并发症。对患者经济及身体造成负担。此外，VEGF有神经营养作用，如果使用过度，可能会对神经元造成损伤。
PD-1(Programmed death protein 1)程序性细胞死亡蛋白受体1，是Ⅰ型跨膜受体，属于免疫球蛋白超家族。在胸腺细胞、外周CD4+、CD8+、NK T细胞、B细胞、巨噬细胞和树突状细胞上表达。是重要的免疫检查点分子，在免疫监视，免疫赦免等方面发挥重要作用。在肿瘤治疗领域，阻断PD-1治疗发挥了重要作用。阻断PD-1可能会加重中枢神经系统炎症。PD-1对视网膜神经炎症的治疗作用研究较少，目前尚无采用PD-1治疗新生血管的报道。
本发明探索PD-1对小胶质细胞的调控可作为新生血管治疗的新方向。
发明内容
为了解决现有技术存在的技术缺陷，本发明提供了PD-1作为制备治疗眼部脉络膜新生血管药物的应用，通过抑制小胶质细胞过度激活找到一种抑制眼内新生血管的方法。
所述的治疗眼部脉络膜新生血管为抑制眼部视网膜神经炎症，抑制抑制眼内新生血管的渗漏。
所述的药物包括药学上有效量的PD-1和药学上可接受的载体。
所述的载体选自常用的药用辅料、生理盐水或蒸馏水。
上述用于治疗眼部脉络膜新生血管药物，所述的药物以PD-1为有效成分，向PD-1中加入常规辅料按照常规工艺制成临床上可接受的合剂、胶囊剂、片剂、薄膜剂、滴眼液、注射剂。
进一步的，本发明药物应用于治疗病理性眼内新生血管。
与现有技术比较本发明的有益效果：
本发明提供了PD-1相关制剂治疗眼部新生血管的药物应用，可抑制眼部视网膜神经炎症，抑制眼内新生血管的渗漏。
附图说明
图1为PD-1对激光诱导小鼠新生血管的治疗作用图。
图1-A为实施例1玻璃体腔注射PD-1后对视网膜的光学相干断层扫描图(OCT)，眼底荧光素血管造影图(FFA)，脉络膜铺片IB4免疫荧光染色图(IF)。
图1-A左侧列：OCT检测眼球内注射PD-1和溶剂组眼内新生血管。图1-A中间列：FFA显示球内注射PD-1和溶剂组眼内新生血管渗漏情况。图1-A右侧列：脉络膜铺片IB4染色对比PD-1和溶剂组眼内新生血管。
图1-B为OCT测量两组CNV高度值统计图。
图1-C为PD-1和溶剂组CNV平均渗漏等级统计图。
图1-D为IB4染色测量PD-1和溶剂组CNV面积值统计图。
图2为PD-1对激光诱导小鼠视网膜神经炎症的抑制作用图。
图中，A-E是与对照组相比，激光造模后球内注射溶剂和PD-1组对视网膜炎症因子Cd68,Ccl-2,Il1b,Il6,Tnf mRNA水平的作用。
具体实施方式
以下通过实施例对本发明进行进一步解释说明：PD-1，购买自ABclone公司。
实施例1
1.小鼠腹腔注射1％戊巴比妥钠(40mg/kg)麻醉，使用0.5％托吡卡胺滴眼液扩张瞳孔，激光光凝术采用裂隙灯式二极管激光系统，绿光波长为532nm，功率为100mW，持续时间为100ms，光斑尺寸为100μm。在视神经周围应用4个激光点。用8-10周龄的C57BL/6小鼠在激光诱导新生血管造模后玻璃体注射PD-1，(PD-1蛋白购买自ABclone公司，生理盐水稀释为5ng/μl)，在实验7天后行FFA以及OCT检查结果显示渗漏明显减少。实验结果见图1，图中A左侧列：OCT检测眼球内注射PD-1和溶剂组眼内新生血管。A中间列：FFA显示球内注射PD-1和溶剂组眼内新生血管渗漏情况。A右侧列：脉络膜铺片IB4染色对比PD-1和溶剂组眼内新生血管面积。
由图1的脉络膜铺片结果显示药物处理组用激光诱导出的眼内新生血管与生理盐水溶剂对照组相比明显变小。说明PD-1对小鼠新生血管模型中的新生血管有明显的抑制效果。
2.玻璃体内注射，小鼠被麻醉并使用上述方法扩大其瞳孔。使用30.5号针头(Becton-Dickinson,Houston,TX)，在鼻上缘后方立即穿过结膜和巩膜进行初步穿刺。随后，将32号钝针连接5μl注射器(Hamilton,Reno,NV)通过该切口插入玻璃体腔。标准进样量为1μL。分为以下几组:PD-1(5ng)和载体(仅限生理盐水)。
3.小鼠麻醉并散瞳行眼底荧光素血管造影(FFA)检查时，将光源过渡到蓝色通道，并仔细校准光强。随后，腹腔注射2％荧光素钠溶液1.7ml/kg。随后拍摄的照片记录了FFA图像。对每只实验动物的双眼进行拍摄，确保数据收集的全面。实验后的步骤包括用生理盐水冲洗眼睛，并使用左氧氟沙星滴眼液预防潜在感染。根据拍摄图片(图1)确定渗漏点分级1级，表示“无泄漏”，存在微弱的高荧光或斑点荧光；2级，被称为“可疑渗漏”，表明晚期高荧光没有大小或强度增加；3级，称为“渗漏”，描述了高荧光区域内的荧光强度增加，而大小保持不变的情况；4级，被称为“病理上显著的渗漏”，其特征是荧光强度和大小都增加载体组平均等级2.1，PD-1组平均等级1.3.
4.光学相干断层扫描(OCT)检查:将固定并麻醉好的动物置于升降桌上，使用复方托吡卡胺滴眼液常规散瞳，并用盐酸丙美卡因滴眼液进行表麻，摆好眼位，待瞳孔散大后将医用卡波姆滴眼液凝胶涂于待测眼角膜上，将眼科超显微成像系统光源调整聚焦，调整镜头焦点至视网膜，而后对视网膜进行光学相干断层扫描(OCT)。每只实验动物双眼均进行拍照。实验完成后用生理盐水清洗双眼，并用左氧氟沙星滴眼液滴眼预防感染。ImageJ软件测量视网膜下新生血管的高度，单位(μm)。载体组平均高度37.58μm，PD-1组平均高度53.50μm(图1.B)。
5.采用颈椎脱位法对小鼠实施安乐死，取下眼球，用4％多聚甲醛(PFA)固定2小时。分离视网膜和RPE-脉络膜复合体，进行通透和封闭。随后，将一抗(抗iba1)在4℃下孵育24小时。一抗孵育后，样品随后与二抗山羊抗兔AlexaFluorTM 647(1:1000稀释)孵育2小时。对于RPE/脉络膜样本，使用IB4(1:500稀释，Sigma-Aldrich)进行染色。经过三次PBS洗涤后，将视网膜和RPE/脉络膜样本小心地平放在玻璃显微镜载玻片上进行成像。采用ImageJ软件进行盲法图像分析，定量评估激光病变面积，载体组平均面积21209μm2，PD-1组平均面积37946μm2(图1.C)。
6.小鼠视网膜样本取出后立即快速冷冻。总RNA提取采用美国EZBioscience公司组织RNA纯化试剂盒。随后，利用EZscript Reverse Transcription Mix II withgDNARemover(EZBioscience,USA)合成cDNA。采用Bio-Rad RT-PCR系统(Hercules,USA)和2×SYBR Green qPCR Master Mix进行基因表达分析。β-肌动蛋白作为内参。用2^-ΔΔCt方法定量测定基因表达的相对变化。每个样本都进行了三次分析，所提供的数据代表了三次独立评估的平均值(见图2)。
上述实验结果显示，PD-1眼内注射后，新生血管面积、高度均较对照组减轻，并且PD-1可以抑制激光诱导上调的视网膜炎症因子mRNA水平。根据上述实验，证明PD-1可抑制视网膜炎症，从而抑制眼内新生血管，可辅助治疗湿性黄斑病变。
Claims (6)
1.PD-1在制备治疗眼部脉络膜新生血管药物中的应用。
2.根据权利要求1所述的应用，其特征在于所述的治疗眼部脉络膜新生血管为抑制眼部视网膜神经炎症，抑制眼内新生血管的渗漏。
3.根据权利要求1所述的应用，其特征在于所述的药物包括药学上有效量的PD-1和药学上可接受的载体。
4.根据权利要求3所述的应用，其特征在于所述的载体选自常用的药用辅料、生理盐水或蒸馏水。
5.一种用于治疗眼部脉络膜新生血管的药物，所述的药物以PD-1为有效成分，向PD-1中加入常规辅料按照常规工艺制成临床上可接受的制剂。
6.根据权利要求5所述的药物，其特征在于所述的制剂为滴眼液、注射剂、合剂、胶囊剂、片剂、薄膜剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311855472.0A CN118059213A (zh) | 2023-12-29 | 2023-12-29 | Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311855472.0A CN118059213A (zh) | 2023-12-29 | 2023-12-29 | Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118059213A true CN118059213A (zh) | 2024-05-24 |
Family
ID=91096241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311855472.0A Pending CN118059213A (zh) | 2023-12-29 | 2023-12-29 | Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118059213A (zh) |
-
2023
- 2023-12-29 CN CN202311855472.0A patent/CN118059213A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neelam et al. | Choroidal neovascularization in pathological myopia | |
| AU2018314280B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| US20140011809A1 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops | |
| Tang et al. | Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma | |
| Ahmadabadi et al. | Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| CN104411678A (zh) | 用于治疗糖尿病性视网膜病及其他眼科疾病的方法 | |
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| CA3031457C (en) | Multikinase inhibitors and uses in ocular fibrosis | |
| US20210260091A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
| JP2023509336A (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| CN118059213A (zh) | Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 | |
| Chang et al. | Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection | |
| Narayanaswamy et al. | Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs | |
| US11951115B2 (en) | Methods of treating retinal vasculopathies | |
| CN110898065A (zh) | 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途 | |
| Jovanović et al. | Quantitative analysis of uveitis macular edema in multiple sclerosis patients receiving deep posterior sub-Tenon triamcinolone acetonide injection | |
| Yadgari et al. | Pretreatment with frequent topical betamethasone in Ahmed glaucoma valve implantation | |
| Kim et al. | Delayed-onset retrobulbar hemorrhage and glaucoma drainage device extrusion in a patient on anticoagulation: a case report | |
| Elsayed | Comparisons of Ranibizumab Injection and Dexamethasone Implant in Macular Oedema Secondary to Central Retinal Vein Occlusion | |
| Wang et al. | Treatment of glaucoma complicated with nodular scleritis with Cyspin: a case report and literature | |
| RU2541834C1 (ru) | Способ лечения "влажной" формы возрастной макулярной дегенерации | |
| Lin | Observation on the clinical effect of cataract phacoemulsification combined with intraocular lens implantation | |
| NADU | CLINICAL STUDY ON THE SAFETY AND EFFICACY OF INTRAVITREAL TRIAMCINOLONE FOR RECALCITRANT MACULAR EDEMA IN SOUTH INDIAN POPULATION | |
| AU2021451276A1 (en) | Pharmaceutical use of cord blood immunosuppressive cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |